GSK plc announced that the FDA approved its drug Exdensur (depemokimab-ulaa) for severe asthma treatment on December 16, 2025, highlighting a significant 58% reduction in asthma attacks in clinical trials. This is a major event as it introduces a novel treatment option for the 2 million Americans suffering from severe asthma.